Market Access Reuters Europe 2025: Trade-offs in European launch sequencin... At Reuters, industry stakeholders discussed how, especially in light of the current tariff crisis, Europe must operate as a unit when pricing drugs.
News ASCO 25: Braftovi shows "unprecedented" survival gain Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in the BREAKWATER trial, setting up full FDA approval.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.